Cronos Group Inc., through its subsidiary CGM B.V., entered into an amendment to the Share Sale and Purchase Agreement for the acquisition of CanAdelaar B.V. The Second SPA Amendment extends the Long Stop Date from September 9, 2026, to October 15, 2026. This adjustment provides additional time to close the transaction involving one of ten licensed cannabis growers in the Dutch Controlled Cannabis Supply Chain Experiment. Cronos Group Inc. operates in the cannabis industry and is a leading producer and distributor of cannabis products.

Cronos Group Inc. reported financial results for its second quarter ended June 30, 2026, announcing record net revenue of $53.0 million, a 58% increase from the prior year period. The company achieved gross profit of $28.5 million and Adjusted EBITDA of $13.1 million, while reporting net income of $35.7 million compared to a net loss in the previous year. During the first half of 2026, Cronos repurchased 12.3 million shares under its active share repurchase program. The company also provided an update on regulatory matters in Israel, noting that while a new anti-dumping investigation was initiated in August 2026 regarding medical cannabis imports from Canada, the prior investigation was terminated. Additionally, the pending acquisition of CanAdelaar B.V. remains subject to Dutch regulatory clearance with an expected close in the second half of 2026. Cronos Group Inc. is a global cannabis company focused on scaling leading consumer goods products through research and development and innovation.